Reyes Bernabé

606 total citations
10 papers, 71 citations indexed

About

Reyes Bernabé is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Radiology, Nuclear Medicine and Imaging. According to data from OpenAlex, Reyes Bernabé has authored 10 papers receiving a total of 71 indexed citations (citations by other indexed papers that have themselves been cited), including 6 papers in Pulmonary and Respiratory Medicine, 6 papers in Oncology and 3 papers in Radiology, Nuclear Medicine and Imaging. Recurrent topics in Reyes Bernabé's work include Lung Cancer Treatments and Mutations (4 papers), Radiomics and Machine Learning in Medical Imaging (3 papers) and Lung Cancer Diagnosis and Treatment (3 papers). Reyes Bernabé is often cited by papers focused on Lung Cancer Treatments and Mutations (4 papers), Radiomics and Machine Learning in Medical Imaging (3 papers) and Lung Cancer Diagnosis and Treatment (3 papers). Reyes Bernabé collaborates with scholars based in Spain, Italy and France. Reyes Bernabé's co-authors include Florentino Hernándo, Javier de Castro, Bartomeu Massutí, Amelia Insa, Virginia Calvo, J.L. González-Larriba, Alex Martínez‐Martí, Joaquim Bosch‐Barrera, Ernest Nadal and Raquel Benítez and has published in prestigious journals such as Journal of Clinical Oncology, Annals of Oncology and Lung Cancer.

In The Last Decade

Reyes Bernabé

9 papers receiving 70 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Reyes Bernabé Spain 4 54 50 17 8 4 10 71
Adrienne Bettini Switzerland 4 57 1.1× 61 1.2× 11 0.6× 4 0.5× 6 1.5× 10 74
Ignacio Casarini Türkiye 5 55 1.0× 61 1.2× 11 0.6× 4 0.5× 3 0.8× 10 78
Anna Pous Spain 4 38 0.7× 19 0.4× 15 0.9× 10 1.3× 5 1.3× 7 61
Archana Ajmera United States 3 36 0.7× 38 0.8× 18 1.1× 9 1.1× 5 1.3× 13 49
Hema Chavan United Kingdom 3 27 0.5× 43 0.9× 10 0.6× 11 1.4× 2 0.5× 3 66
Qilong Zhang China 4 41 0.8× 29 0.6× 10 0.6× 11 1.4× 1 0.3× 9 50
Ricardo Velasquez United States 3 26 0.5× 47 0.9× 21 1.2× 14 1.8× 3 0.8× 4 84
O.T. Brustugun Norway 5 45 0.8× 48 1.0× 11 0.6× 5 0.6× 2 0.5× 5 72
Sophia J. Luo United States 5 43 0.8× 66 1.3× 10 0.6× 8 1.0× 7 1.8× 10 94
Daphne Wang United States 2 57 1.1× 39 0.8× 6 0.4× 4 0.5× 6 1.5× 2 69

Countries citing papers authored by Reyes Bernabé

Since Specialization
Citations

This map shows the geographic impact of Reyes Bernabé's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Reyes Bernabé with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Reyes Bernabé more than expected).

Fields of papers citing papers by Reyes Bernabé

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Reyes Bernabé. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Reyes Bernabé. The network helps show where Reyes Bernabé may publish in the future.

Co-authorship network of co-authors of Reyes Bernabé

This figure shows the co-authorship network connecting the top 25 collaborators of Reyes Bernabé. A scholar is included among the top collaborators of Reyes Bernabé based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Reyes Bernabé. Reyes Bernabé is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

10 of 10 papers shown
1.
Paz‐Ares, Luis, Stephen V. Liu, Solange Peters, et al.. (2025). Lurbinectedin (lurbi) + atezolizumab (atezo) as first-line (1L) maintenance treatment (tx) in patients (pts) with extensive-stage small cell lung cancer (ES-SCLC): Primary results of the phase 3 IMforte trial.. Journal of Clinical Oncology. 43(16_suppl). 8006–8006. 2 indexed citations
2.
Ponce-Aix, Santiago, Alejandro Navarro, Laura Mezquita, et al.. (2025). Safety and efficacy of lurbinectedin plus atezolizumab as second-line treatment for advanced small-cell lung cancer: Results of the 2SMALL phase 1/2 study (NCT04253145).. Journal of Clinical Oncology. 43(16_suppl). 8013–8013.
3.
Gregorc, Vanesa, María González‐Cao, Stefania Salvagni, et al.. (2024). KROCUS: A phase II study investigating the efficacy and safety of fulzerasib (GFH925) in combination with cetuximab in patients with previously untreated advanced KRAS G12C mutated NSCLC.. Journal of Clinical Oncology. 42(17_suppl). LBA8511–LBA8511. 14 indexed citations
4.
Masip, J. Remon, Paolo Bironzo, N. Girard, et al.. (2024). LBA83 PECATI: A phase II trial to evaluate the efficacy and safety of lenvatinib in combination with pembrolizumab in pretreated advanced B3-thymoma and thymic carcinoma. Annals of Oncology. 35. S1270–S1270. 3 indexed citations
5.
Calvo, Virginia, Enric Carcereny, Delvys Rodríguez‐Abreu, et al.. (2024). Family history of cancer and lung cancer: Utility of big data and artificial intelligence for exploring the role of genetic risk. Lung Cancer. 195. 107920–107920. 3 indexed citations
6.
Serna‐Blasco, Roberto, Ernest Nadal, J.L. González-Larriba, et al.. (2024). 138P Faecalibacterium prausnitzii enhances tumor response to perioperative nivolumab and chemotherapy. ESMO Open. 9. 102725–102725. 1 indexed citations
7.
Masip, J. Remon, Benjamin Besse, Santiago Ponce Aix, et al.. (2022). LBA51 Osimertinib treatment based on plasma T790M monitoring in patients with EGFR-mutant non-small cell lung cancer (NSCLC): EORTC Lung Cancer Group 1613 APPLE phase II randomized clinical trial. Annals of Oncology. 33. S1419–S1419. 3 indexed citations
8.
Timilsina, Mohan, Dirk Fey, María Torrente, et al.. (2022). Integration of Clinical Information and Imputed Aneuploidy Scores to Enhance Relapse Prediction in Early Stage Lung Cancer Patients.. PubMed. 2022. 1062–1071. 2 indexed citations
9.
Nadal, Ernest, J.L. González-Larriba, Alex Martínez‐Martí, et al.. (2022). Nivolumab + chemotherapy versus chemotherapy as neoadjuvant treatment for resectable stage IIIA NSCLC: Primary endpoint results of pathological complete response (pCR) from phase II NADIM II trial.. Journal of Clinical Oncology. 40(16_suppl). 8501–8501. 40 indexed citations
10.
Nadal, Ernest, Amelia Insa, J. Casal, et al.. (2022). Multimodal prediction of response to neoadjuvant nivolumab and chemotherapy for surgically resectable stage IIIA non–small cell lung cancer.. Journal of Clinical Oncology. 40(16_suppl). 8542–8542. 3 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Adrienne Bettini Breakdown of academic impact, for papers by Ignacio Casarini Breakdown of academic impact, for papers by Anna Pous Breakdown of academic impact, for papers by Archana Ajmera Breakdown of academic impact, for papers by Hema Chavan Breakdown of academic impact, for papers by Qilong Zhang Breakdown of academic impact, for papers by Ricardo Velasquez Breakdown of academic impact, for papers by O.T. Brustugun Breakdown of academic impact, for papers by Sophia J. Luo Breakdown of academic impact, for papers by Daphne Wang
Rankless by CCL
2026